

JEENA SIKHO LIFECARE LIMITED

(Formerly known as Jeena Sikho Lifecare Private Limited)

REGD OFFICE: SCO-11, Kalgidhar Enclave, Baltana, Zirakpur, Punjab-140604, 01762-513185
Branch: B-26, Opp. Metro Pillar No. 223, Rohtak Road, New Multan Nagar, Delhi - 110056
CIN NO.: L52601PB2017PLC046545 Email ID.: cs@jeenasikho.com

Ref. No.

Dated

Date: 11/10/2024

To,

| | |
|---|--|
| The Manager-Listing Compliance National Stock Exchange India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla complex, Bandra (E), Mumbai 400051. | Scrip Code : JSLL ISIN : INE0J5801011 |
|---|--|

Subject: Outcome of Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Ref: Incorporation of Subsidiary

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that the Board of Directors at their meeting held on today i.e. Friday, 11th October, 2024 inter alia considered approved the following:

1. Incorporation of a subsidiary company with the Name and style of “**Integrated IVF and Fertility Research Institute Private Limited**” in India as private limited company.
2. Incorporation of a subsidiary company with the Name and style of “**Integrated Cancer Research Institute Private Limited**” in India as private limited company.

The details required under regulation 30 of SEBI Listing Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 as modified by SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as **Annexure – A and Annexure B**.

Board Meeting commenced at 03:00 P.M. and concluded at 3:30 P.M.

You are requested to kindly take the above on your records

Thank you,
Yours faithfully,

FOR, JEENA SIKHO LIFECARE LIMITED

Manish Grover
Managing Director
DIN: 07557886

ANNEXURE – A

Details required under regulation 30 of SEBI Listing Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 as modified by SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

| S. No. | Items to be disclosed | Details |
|---------------|--|---|
| 1. | Name of the target entity, details in brief such as size, turnover etc. | Integrated IVF and Fertility Research Institute Private Limited. Proposed Authorized Share Capital: Rs. 1,00,000 (Rupees One lakhs only). Company shall own 5,100 equity shares of Rs. 10 (Ten) each in the Target Entity (Subsidiary Co.). Turnover: Not applicable since this is Subsidiary Company yet to be Incorporate. |
| 2. | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”. | The Subsidiary Company once incorporated will be a related party of the Company. The shares of the subsidiary company shall be subscribed at arm’s length price i.e. face value. Promoter/promoter group/ group companies will not have any equity interest in the entity. |
| 3. | Industry to which the entity being acquired belongs | Health Care |
| 4. | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | The proposed subsidiary company shall carry out business in the field of Integrated IVF and Fertility Research. |
| 5. | Brief details of any governmental or regulatory approvals required for the acquisition. | Not Applicable. |
| 6. | Indicative time period for completion of the acquisition. | Subject to requisite approvals, it is expected to be completed by November, 2024 |
| 7. | Nature of consideration - whether cash consideration or share swap and details of the same. | Cash |
| 8. | Cost of acquisition or the price at which the shares are acquired. | Subscription to 5,100 equity share of the Company shall be in cash of Rs. 51,000/-. |
| 9. | Percentage of shareholding/ control acquired and/ or number of shares acquired. | The Company owns 51% of the shareholding in the new entity viz. Integrated IVF and Fertility Research Institute Private Limited. |
| 10. | Brief background about the entity acquired in terms of products/line of business acquired, | Not Applicable since the company is yet to be incorporated. |

| | | |
|--|--|--|
| | date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief). | |
|--|--|--|

FOR, JEENA SIKHO LIFECARE LIMITED

Manish Grover
Managing Director
DIN: 07557886

ANNEXURE – B

Details required under regulation 30 of SEBI Listing Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 as modified by SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

| S.No. | Items to be disclosed | Details |
|--------------|--|--|
| 1. | Name of the target entity, details in brief such as size, turnover etc. | Integrated Cancer Research Institute Private Limited. Proposed Authorized Share Capital: Rs. 1,00,000 (Rupees One lakhs only). Company shall own 6,000 equity shares of Rs. 10 (Ten) each in the Target Entity (Subsidiary Co.). Turnover: Not applicable since this is Subsidiary Company yet to be Incorporate. |
| 2. | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”. | The Subsidiary Company once incorporated will be a related party of the Company. The shares of the subsidiary company shall be subscribed at arm’s length price i.e. face value. Promoter/promoter group/ group companies will not have any equity interest in the entity. |
| 3. | Industry to which the entity being acquired belongs | Health Care |
| 4. | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | The proposed subsidiary company shall carry out business in the field of Cancer treatment and its research. |
| 5. | Brief details of any governmental or regulatory approvals required for the acquisition. | Not Applicable. |
| 6. | Indicative time period for completion of the acquisition. | Subject to requisite approvals, it is expected to be completed by November, 2024 |
| 7. | Nature of consideration - whether cash consideration or share swap and details of the same. | Cash |
| 8. | Cost of acquisition or the price at which the shares are acquired. | Subscription to 6,000 equity share of the Company shall be in cash of Rs. 60,000/-. |
| 9. | Percentage of shareholding/ control acquired and/ or number of shares acquired. | The Company owns 60% of the shareholding in the new entity viz. Integrated Cancer Research Institute Private Limited. |
| 10. | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years | Not Applicable since the company is yet to be incorporated. |

| | | |
|--|---|--|
| | turnover, country in which the acquired entity has presence and any other significant information (in brief). | |
|--|---|--|

FOR, JEENA SIKHO LIFECARE LIMITED

Manish Grover
Managing Director
DIN: 07557886